Literature DB >> 28427960

Construct and expression of recombinant domains I/II of dengue virus- 2 and its efficacy to evaluate immune response in endemic area: Possible use in prognosis.

Alfredo Eduardo Montes-Gómez1, Hector Vivanco-Cid2, José Bustos-Arriaga3, Mussaret Bano Zaidi4, Jazmin Garcia-Machorro5, Benito Gutierrez-Castañeda6, Leticia Cedillo-Barron7.   

Abstract

The envelope (E) protein from DENV, contain three functional and structural domains (DI, DII and DIII). Some studies suggest that neutralizing antibodies during natural DENV infection are predominantly against DI and DII, in contrast, low proportion of the antibodies were against DIII. Thus it is necessary to establish the proportion of human antibodies against DENV E protein that bind to DI and DII during the normal course of infection; as an indicator of the quality of the antibody response and to further design new vaccine candidates for DENV. The aim of this study was to express recombinant proteins harboring a 240-aminoacid fragment of the E protein from DI and DII of DENV serotypes 2 and 3 in a eukaryotic S2 system. Further, we evaluate the antibodies against these antigens in samples from patients in acute phase of DF or DHF and compare it with the response of samples from healthy individuals from the same endemic areas and samples from healthy individuals from a non-endemic area (EA and NEA, respectively). These results suggest that the presence of antibodies against rEDI/DII might be used to identify patients at risk for severe disease.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody response; Dengue virus; Specific antibodies

Mesh:

Substances:

Year:  2017        PMID: 28427960     DOI: 10.1016/j.actatropica.2017.04.006

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  1 in total

1.  Cross-Reaction, Enhancement, and Neutralization Activity of Dengue Virus Antibodies against Zika Virus: A Study in the Mexican Population.

Authors:  Mayra R Montecillo-Aguado; Alfredo E Montes-Gómez; Julio García-Cordero; Josselin Corzo-Gómez; Héctor Vivanco-Cid; Gabriela Mellado-Sánchez; J Esteban Muñoz-Medina; Benito Gutiérrez-Castañeda; Leopoldo Santos-Argumedo; César González-Bonilla; Leticia Cedillo-Barrón
Journal:  J Immunol Res       Date:  2019-09-02       Impact factor: 4.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.